FINWIRES · TerminalLIVE
FINWIRES

Market Chatter: IndiGo in Talks With Embraer for Potential E2 Jet Order

By

InterGlobe Aviation (BOM:539448), parent of India's largest airline IndiGo, is in talks with Brazil's Embraer over a potential order for dozens of E2 regional jets, Bloomberg News reported, citing people familiar with the matter.

IndiGo is weighing aircraft to replace its ATR turboprop fleet and expand capacity, though discussions are in early stages and may not result in a deal, according to the report.

The potential order could be worth billions of dollars before customary industry discounts and would be Embraer's largest deal in India if completed, Bloomberg said.

Embraer declined to comment on' request for comment, while IndiGo did not immediately respond.

(Market Chatter news is derived from conversations with market professionals globally. This information is believed to be from reliable sources but may include rumor and speculation. Accuracy is not guaranteed.)

Related Articles

Asia

Aspial Lifestyle's H1 Attributable Profit Surges 88%

Aspial Lifestyle's (SGX:5UF) recorded an 88% rise in attributable profit in the first half of 2026 to SG$52.4 million from SG$27.9 million a year prior.Earnings per share stood at SG$0.0277, up from SG$0.015 previously, according to a Friday filing with the Singapore bourse.Revenue jumped 26% to SG$464.2 million from SG$367.2 million in the year-ago period.

SGX:5UF
Asia

Sino Biopharma Unit Gets China Nod to Market Lung Cancer Drug

Sino Biopharmaceutical (HKG:1177) unit Chia Tai Tianqing Pharmaceutical Group's Benmelstobart Injection obtained marketing approval from China's National Medical Products Administration, according to a Friday Hong Kong bourse filing.The approval is for use of the drug in combination with chemotherapy and sequentially followed by Anlotinib Hydrochloride Capsules for the first-line treatment of locally advanced or metastatic squamous non-small cell lung cancer.

HKG:1177
Asia

Lygend Resources Gets CSRC Nod for China Listed-Share IPO

Lygend Resources & Technology (HKG:2245) obtained approval for its registration application related to its China listed-share initial public offering from the China Securities Regulatory Commission (CSRC).The share offering is subject to various conditions, including certain final regulatory approvals, according to a Friday Hong Kong bourse filing.

HKG:2245